Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trialChristopher J. Sweeney, Andrew Martin, Leanna Cheung et al.|The Lancet Oncology|2023Cited by 195
Sites of metastasis and survival in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).Shaan Dudani, Daniel Yick Chin Heng, Guillermo de Velasco et al.|Journal of Clinical Oncology|2020Cited by 31
Acute Cardiogenic Shock Induced by Infusional 5-FluorouracilJeffrey Sulpher, Christopher Johnson, Franco Dattilo et al.|Case Reports in Oncological Medicine|2014Cited by 11
Active surveillance in metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis).Igal Kushnir, M. Neil Reaume, Naveen S. Basappa et al.|Journal of Clinical Oncology|2019Cited by 7
The timing of docetaxel initiation in metastatic castrate-sensitive prostate cancer and the rate of chemotherapy-induced toxicityIgal Kushnir, M. Neil Reaume, Michael Ong et al.|Medical Oncology|2019Cited by 7